Edgestream Partners L.P. bought a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,450 shares of the health services provider's stock, valued at approximately $412,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Trexquant Investment LP raised its holdings in Amedisys by 1,317.8% in the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock valued at $7,964,000 after buying an additional 81,532 shares during the last quarter. Fifth Third Bancorp raised its holdings in Amedisys by 68.1% in the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after buying an additional 141 shares during the last quarter. Teacher Retirement System of Texas bought a new position in Amedisys in the 1st quarter valued at approximately $817,000. Schonfeld Strategic Advisors LLC raised its holdings in Amedisys by 17.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider's stock valued at $409,000 after buying an additional 671 shares during the last quarter. Finally, Deutsche Bank AG raised its holdings in Amedisys by 22.7% in the 4th quarter. Deutsche Bank AG now owns 2,524 shares of the health services provider's stock valued at $229,000 after buying an additional 467 shares during the last quarter. Institutional investors own 94.36% of the company's stock.
Amedisys Price Performance
Shares of NASDAQ:AMED opened at $97.46 on Friday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. The stock's fifty day simple moving average is $96.01 and its two-hundred day simple moving average is $93.75. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The stock has a market cap of $3.20 billion, a PE ratio of 35.96, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94.
Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.03 EPS. As a group, analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Wall Street Zen downgraded shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Amedisys currently has an average rating of "Hold" and an average price target of $100.75.
Check Out Our Latest Analysis on Amedisys
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
